Table 3. Effect of miltefosine lipid nanocapsule formulations (MFS-LNCs) on S. mansoni worm burden as compared with control groups(n = 6).
F* = 78.369 (p<0.001).
| Animal group / Formulation code | ||||||||
|---|---|---|---|---|---|---|---|---|
| Worm load | Infected untreated Control | MFS-sol Control | Group I | Group II | Group III | Group IV | Group V | Group VI |
| MFS-LNC | MFS-LNC- CTAB+ | MFS-LNC- CS | MFS-LNC- DCP¯ | MFS-LNC- -OA | MFS-LNC- OA-CTAB + | |||
| Min. | 37.0 | 34.0 | 7.0 | 4.0 | 6.0 | 15.0 | 2.0 | 15.0 |
| Max. | 41.0 | 37.0 | 19.0 | 8.0 | 14.0 | 30.0 | 6.0 | 22.0 |
| Mean | 39.0 | 35.83 | 12.67 a b | 5.17 a b c | 10.0 a b d | 22.50 a b c d e | 4.50 a b c e f | 18.0 a b c d e f g |
| SD | 1.41 | 1.17 | 5.01 | 1.83 | 3.41 | 6.28 | 1.64 | 2.61 |
| Median | 39.0 | 36.0 | 12.0 | 4.0 | 10.0 | 22.50 | 5.0 | 17.50 |
| % R 1 | 8.13 | 67.51 | 86.74 | 74.36 | 42.31 | 88.46 | 53.85 | |
| % R 2 | 64.64 | 85.57 | 72.09 | 37.20 | 87.44 | 49.76 | ||
* F test (ANOVA). % R1: % reduction in each of the study groups relative to infected control. %R2:% reduction in each of the study groups relative to miltefosine solution control
a: significant with infected untreated control
b: significant with MFS solution control
c: significant with group I
d: significant with group II
e: significant with group III
f: significant with group IV
g: significant with group V